載入中
NASDAQHealthcareBiotechnology
最新資料
US$5.95
+US$0.22 · +3.84%
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
前收盤價
US$5.95
+US$0.22 · +3.84%
盤中時間採用ET。市場資料可能有所延遲。
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
日內區間
目前US$5.95
52週區間
目前US$5.95
盤中時間採用ET。市場資料可能有所延遲。
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
日內區間
目前US$5.95
52週區間
目前US$5.95
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 3348.2萬 USD | 263.8萬 USD | 276萬 USD | 353.3萬 USD | −78.2萬 USD |
| 銷貨成本 | 19萬 USD | 20.4萬 USD | 18.6萬 USD | 32.2萬 USD | 19.9萬 USD |
| 毛利 | 3329.2萬 USD | 243.4萬 USD | 257.4萬 USD | 321.1萬 USD | −98.1萬 USD |
| 研究與開發 | 5818.5萬 USD | 4280.4萬 USD | 3382.2萬 USD | 2194.5萬 USD | 1289萬 USD |
| 銷售、一般及管理費用 | 2691.4萬 USD | 2393.1萬 USD | 2025.8萬 USD | 1392.3萬 USD | 792.8萬 USD |
| 營業費用 | 8509.9萬 USD | 6673.5萬 USD | 5408萬 USD | 3586.8萬 USD | 2081.8萬 USD |
| 利息收入 | — | 335.6萬 USD | 384.9萬 USD | 5萬 USD | — |
| 利息支出 | 114.8萬 USD | — | — | — | 92.7萬 USD |
| 折舊和攤銷 | 32.7萬 USD | 30.8萬 USD | 28.7萬 USD | 22.2萬 USD | 18.1萬 USD |
| 營業利益 | −5180.7萬 USD | −6430.1萬 USD | −5150.6萬 USD | −3265.7萬 USD | −2179.9萬 USD |
| 淨利 | −5270.1萬 USD | −6102.4萬 USD | −4912萬 USD | −3360.8萬 USD | −2301.4萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$10.75
上漲空間 80.67%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI740.91萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM574.66萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF251.31萬0.00%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO213.64萬0.02%139.17億 USD0.24%US$356.78+0.94%
Schwab U.S. Small-Cap ETFSCHA132.9萬0.01%218.24億 USD0.03%US$32.79+0.40%
Simplify Propel Opportunities ETFSURI130.54萬1.72%7606.44萬 USD2.82%US$17.06-0.14%
Vanguard Russell 2000 ETFVTWO115.78萬0.01%180億 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC71.45萬0.05%13.17億 USD0.60%US$183+0.11%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHASimplify Propel Opportunities ETFSURIVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
